Infinity Pharmaceuticals
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$89.9
-0.0
-0.44
$2.33M
30
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Recently from Cashu
Infinity Pharmaceuticals Eyes Home Hydrotherapy Trend for Supportive Care and Trial Endpoints
Pharma watches rise of home hydrotherapy as a patient care adjunct Infinity Pharmaceuticals is tracking a surge in home-based wellness that is prompting wider industry attention to hydrotherapy and ad…
Home Hydrotherapy Boom Creates Biotech Opportunities for Infinity Pharmaceuticals
Headline: Home Hydrotherapy Boom Signals New Adjacent Opportunities for Biotech Firms Like Infinity Pharmaceuticals Main topic — Consumer wellness surge creates translational openings for biopharma Th…
Infinity Ventures Backs Pinch's AI to Combat E-commerce Return Abuse Challenges
Innovative Solutions to E-commerce Challenges: Pinch's AI-Driven Approach In a significant move to tackle the escalating challenges of return abuse in retail, San Francisco-based Pinch has successfull…
Infinity Ventures Backs Pinch's AI Solutions to Revolutionize Retail Returns
Pinch Revolutionizes Retail Returns with AI Solutions In a significant development for the e-commerce landscape, Pinch, an AI-driven post-purchase intelligence platform based in San Francisco, success…